SCHEMBL5493674

SCHEMBL5493674

CCCCOC(=O)N1CCC[C@@H]1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.59
LMNA P02545 2/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP2C19 P33261 1/20 0.49
ACE P12821 9/20 0.48
ACE2 Q9BYF1 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
REN P00797 3/20 0.46
KDM4E B2RXH2 1/20 0.46
F2 P00734 1/20 0.46
LTA4H P09960 1/20 0.46
MAPT P10636 1/20 0.46
PEPD P12955 1/20 0.46
ALOX15 P16050 1/20 0.46
PTGS1 P23219 1/20 0.46
HTR2A P28223 1/20 0.46
PTGS2 P35354 1/20 0.46
HRH1 P35367 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695608 1.00 RAB9A (0.62) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL2634067 1.00 RAB9A (0.62) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL9464451 0.98 RAB9A (0.61) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL18209676 0.96 RAB9A (0.58) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL7815566 0.95 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL7811720 0.95 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL16124534 0.95 RAB9A (0.61) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL3710312 0.95 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL18106053 0.94 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL7771246 0.94 RAB9A (0.59) RAB9AL3MBTL1LMNAHSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119875045-A Pyrenyl covalent organic framework material and preparation method and application thereof 中国石油天然气股份有限公司 2025-04-25 CN disclosed
CN-107847765-A The piperidine derivative of 1,4 substitutions 赛福伦公司 2018-03-27 CN disclosed
CN-103998429-B Substituted phenyl amines as CCR (4) antagonist 凯莫森特里克斯股份有限公司 2016-12-07 CN disclosed
CN-103998429-A Substituted anilines as ccr(4) antagonists CHEMOCENTRYX INC 2014-08-20 CN disclosed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP disclosed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO disclosed
WO-2006071079-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO disclosed
EP-1087935-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2001-04-04 EP disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 WO disclosed
WO-1999065866-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 1999-12-23 WO disclosed